eligibility_summary
Eligible: adults (≥18) with chronic hypersensitivity pneumonitis confirmed by multidisciplinary team per CHEST, with ≥5% FVC decline after ≥6 months of antigen avoidance plus immunosuppression (corticosteroids and azathioprine). Exclude: rituximab hypersensitivity, severe heart failure, moderate/severe pulmonary hypertension, fibrotic HP, pregnancy, active infection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Rituximab (MabThera), a chimeric anti‑CD20 monoclonal antibody (biologic immunotherapy), given IV 1 g on days 0 and 15 in refractory chronic hypersensitivity pneumonitis. Mechanism of action: binds CD20 on pre‑B and mature B lymphocytes and depletes them via complement‑dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, and apoptosis, lowers autoantibody/immune‑complex formation, antigen presentation, and B‑cell–derived cytokines. Target cells/pathways: CD20+ B cells, downstream modulation of humoral immunity and T‑cell activation that drive immune‑mediated alveolitis/granulomatous lung inflammation. Primary efficacy readout: FVC change from pre‑ to post‑treatment.